跳至主要内容
临床试验/NCT00161889
NCT00161889已完成2 期

Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years

Pfizer38 个研究点 分布在 1 个国家目标入组 615 人开始时间: 2002年2月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
Pfizer
入组人数
615
试验地点
38

研究概览

简要总结

The purpose of this study is to investigate the safety and immunogenicity of the third vaccination with one of three different concentrations of a TBE vaccine in all volunteers who completed two vaccinations in one of the three treatment groups of Baxter study 205 (safety and immunogenicity of two vaccinations with FSME IMMUN NEW in healthy volunteers aged 6 to 16 years).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double

入排标准

年龄范围
6 Years 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • There are no specific exclusion criteria for this study entry. However volunteers will be assessed for eligibility to receive a third vaccination.
  • Volunteers will be excluded from vaccination and consecutive visits in this study if they:
  • Are not clinically healthy, (i. e. the physician would have reservations vaccinating with FSME IMMUN NEW outside the scope of a clinical trial)
  • Have already been administered a third TBE vaccination elsewhere after the two vaccinations in Baxter study 205
  • Have had an allergic reaction to one of the components of the vaccine since the last vaccination in Baxter study 205
  • Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment (e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence immunological functions
  • Have received banked human blood or immunoglobulins within one month of study entry
  • Are known to be HIV positive (a special HIV test is not required for the purpose of the study) since the last visit of Baxter study 205
  • Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the last visit in Baxter study 205
  • Had received an investigational new drug within 6 weeks prior to study start
  • If female and capable of bearing children - have a positive pregnancy test at the first medical examination

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (38)

Loading locations...

相似试验